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Background: Chronic migraine is a neurological condition with a large individual and socioeconomic burden of
disease. The recently completed Phase III REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical
development program established the efficacy and safety of onabotulinumtoxinA as a prophylactic treatment for
chronic migraine patients. However, clinical questions remain. A long-term evaluation study of onabotulinumtoxinA
aims to address some of the remaining questions in the treatment of chronic migraine. The clinical rationale, study
design, and treatment plan of this ongoing study are reviewed in this paper.
Methods/Design: The Chronic migraine OnabotulinuMtoxinA Prolonged Efficacy open Label (COMPEL) study will
enroll approximately 500 adult patients with chronic migraine at international sites. Patients will be evaluated over
108 weeks, following a 4-week baseline period. Qualified subjects will receive 155 U of onabotulinumtoxinA every
12 weeks for 9 open-label cycles. The primary endpoint will be mean change from baseline in frequency of headache
days at 108 weeks. Other endpoints will include additional assessments of the efficacy and safety of onabotulinumtoxinA
and the effect of onabotulinumtoxinA on quality-of-life measures, disability, and health economic outcomes. The impact
of onabotulinumtoxinA on common comorbidities (eg, sleep, anxiety, and fatigue) will also be assessed.
Discussion: Recruitment and enrollment are ongoing. Post-approval, open-label studies are often designed to more
closely resemble clinical practice and provide an opportunity to continue the evaluation of the efficacy and safety of
approved treatments. By creating a large database and analyzing a variety of outcome measures over an extended time
frame, the COMPEL study will seek to contribute substantially to the existing knowledge of the chronic migraine
population and the long-term management of this debilitating disorder.
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Table 1 Study objectives for COMPEL
Primary Objective
To assess mean change from baseline in the frequency of headache
days per 28-day period at 108 weeks (following 9 treatments) using a
patient diary completed via IVRS.
Secondary Objectives
To assess mean change from baseline in the frequency of headache
days for the 28-day period ending at 60 weeks (following 5 treatments).
To assess the efficacy of onabotulinumtoxinA treatment for CM in adult
patients as measured by the mean change from baseline in total HIT-6
score over a 4-week period at 108 weeks (following 9 treatments) and
at 60 weeks (following 5 treatments).
To evaluate the long-term safety and tolerability (9 treatment cycles) of
onabotulinumtoxinA for CM in adult patients.
CM= chronic migraine; HIT-6 = Headache Impact Test-6; IVRS = interactive voice
response system
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Chronic migraine (CM) is a severe neurological disorder
with a global prevalence of approximately 2 % of adults
[1]. According to the International Headache Society,
CM is defined as headache on 15 or more days per
month for more than 3 months (at least 8 days should
meet criteria for migraine without aura or respond to
migraine-specific treatment) [1, 2]. Chronic migraine is
less prevalent than episodic migraine (EM; headache on
<15 days per month), but it has far-reaching individual
and societal impact [1, 2].
Compared with EM patients, patients with CM are
more likely to have severe disability and an inability to
work, function within society, and manage household
chores. Patients with CM report a lower health-related
quality of life (HRQoL), greater lost productive time,
and greater healthcare resource utilization than EM
patients [3–6]. Additionally, psychiatric comorbidities
such as depression and anxiety are more prevalent
among chronic migraineurs than episodic migraineurs
[7]. Other frequent comorbidities include fatigue and
sleep disorders [8]. Given the severe burden of illness
suffered by CM patients, as well as the comorbidities
associated with the condition, it is important to design
studies that aim to improve understanding of treatment
effects for this debilitating disorder.
Currently, onabotulinumtoxinA is the only therapy
specifically approved in the US for prophylaxis of head-
ache in CM patients, and the treatment paradigm and
dosing are specific to this product.
The currently understood mechanism of action of
onabotulinumtoxinA is via interruption of the inflam-
matory cascade of events that results in peripheral
nociceptor sensitization and, subsequently, central
sensitization [9, 10]. With neuronal stimulation, the
peripheral sensory nerve ending releases vesicles storing
substance P, calcitonin gene-related peptide (CGRP),
and other neuropeptides. The fusion of the vesicles
with the nerve membrane requires the formation of the
soluble N-ethylmaleimide-sensitive factor attachment
protein receptor (SNARE) complex, which then facili-
tates the release of their cargo by the process of exo-
cytosis [9, 11]. As demonstrated in preclinical studies
[12], via receptor-mediated endocytosis, onabotulinum-
toxinA enters an intracellular membranous endosome,
translocates across the endosome into the cytoplasm
and cleaves its SNARE protein target, synaptosomal-
associated protein 25 (SNAP-25), which blocks the periph-
eral release of inflammatory neurotransmitters, which in
turn reduces the sensitization of pain nerve fibers [9, 10].
The efficacy and safety of onabotulinumtoxinA in CM
was evaluated over a 56-week period (24-week, double-
blind period, followed by 32 weeks of open-label use) in
the Phase III REsearch Evaluating Migraine ProphylaxisTherapy (PREEMPT) clinical program, the largest study
in CM to date [13]. Compared to placebo, onabotuli-
numtoxinA was more effective in reducing mean fre-
quency of headache days from baseline at every visit
from Week 4 to the primary endpoint of Week 24 (−8.4
onabotulinumtoxinA vs. -6.6 placebo; p < 0.001) [13].
Statistically significant improvements from baseline in
secondary efficacy variables (eg, frequency of migraine
days and moderate or severe headache days, and cumu-
lative hours of headache) were established in patients
treated with onabotulinumtoxinA compared to placebo.
Patients treated with onabotulinumtoxinA also had a
significant reduction in severe (>60) Headache Impact
Test-6™ (HIT-6) scores (p < 0.01) and experienced an im-
provement in HRQoL at all time points, as measured by
the Migraine-Specific Quality-of-Life Questionnaire
(MSQ) (p < 0.001) [13]. Most adverse events reported in
the PREEMPT clinical program were mild to moderate,
and all resolved without permanent sequelae [13].
The goal of the Chronic migraine OnabotulinuMtoxinA
Prolonged Efficacy open Label (COMPEL) study is to test
the following clinical hypotheses: (1) onabotulinumtoxinA
is an efficacious form of headache prophylaxis in adults
with CM, as measured by a reduction from baseline in the
number of headache days over a 28-day period after
108 weeks (9 cycles) of treatment; and (2) onabotulinum-
toxinA has an acceptable safety profile over 108 weeks
(9 cycles) of treatment. Efficacy and safety measures will
be assessed at Week 60 and Week 108. Table 1 summa-
rizes the main objectives of COMPEL. Other exploratory
hypotheses will be tested in the COMPEL trial, including
whether: (1) onabotulinumtoxinA treatment is associated
with improvement in depression (Patient Health Ques-
tionnaire [PHQ-9]), sleep (Pittsburgh Sleep Quality Index
[PSQI]), anxiety (Generalized Anxiety Disorder Assess-
ment [GAD-7]), and fatigue (Fatigue Severity Scale [FSS]);
(2) the benefit of onabotulinumtoxinA treatment is ob-
served in the presence of concomitant prophylactics; (3)
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significant decrease in disability and improvement in
HRQoL; and (4) onabotulinumtoxinA treatment may be
associated with increased productivity and reduced dis-
ability and utilization of healthcare resources by patients.
Methods/design
Study design
The COMPEL study is a single-arm, open-label, multi-
center, post-authorization, prospective study of onabotu-
linumtoxinA use in CM for headache prophylaxis. The
duration of the study is 112 weeks, including a 4-week
baseline period and a 108-week, open-label treatment
intervention phase (Fig. 1). There will be a total of 11 pa-
tient visits, including an initial baseline visit at −4 weeks
(Visit 1), 9 interventional visits (on Day 1 and at Weeks
12, 24, 36, 48, 60, 72, 84, and 96), and a study exit visit at
Week 108 (Visit 11). Baseline measures of the patient
population will include demographics, medical history,
physical exam, headache history, detailed headache treat-




































































Fig. 1 COMPEL study design. ACM-I = Assessment of Chronic Migraine Impac
Severity Scale; GAD-7 = Generalized Anxiety Disorder Assessment; HIT-6 =
IVRS = interactive voice response system; MIDAS =Migraine Disability Assess
v2.1; PHQ-9 = Patient Health Questionnaire-9; PSQI = Pittsburgh Sleep Qualitycollected via interactive voice response system (IVRS).
Diary data will be entered daily during the 4-week baseline
period after Visit 1 and then daily for 28 days, starting
4 weeks prior to Visits 4, 7, 9, and 11.
Study eligibility criteria
Study entry screening will be limited to adult patients who
are 18 years of age or older, have a diagnosis of CM, are in
stable medical condition, are able to follow and comply
with study instructions and required visits, and have a
negative urine pregnancy test, if applicable. Patients
participating in the study may take concurrent medica-
tions such as vitamins, herbal remedies, dietary supple-
ments, and a single oral headache prophylaxis medication
(ie, beta-blocker, calcium channel blocker, angiotensin-
converting enzyme [ACE] inhibitor, aldosterone receptor
blocker, antiepileptic, or tricyclic antidepressant), provided
these medications are documented. Only one concomitant
oral headache prophylaxis medication can be used at any
time during the study. A second oral prophylaxis medica-


































































 Protocol Visits and Measures
ts; ACM-S = Assessment of Chronic Migraine Symptoms; FSS = Fatigue
Headache Impact Test-6; HRU = Healthcare Resource Utilization;
ment Questionnaire; MSQ =Migraine-Specific Quality-of-Life Questionnaire
Index; SF-36 = Short-Form 36 Health Survey; Wk =week
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treatment anytime during the study. Patients that discon-
tinue oral prophylaxis may continue treatment only with
onabotulinumtoxinA (no alternative oral headache prophy-
laxis can be added later) (Table 2).
For patients who are taking oral headache prophylaxis
medication, patient must be on a stable dose and regi-
men of a single oral prophylaxis treatment for at least
4 weeks prior to Visit 2 (Day 1). For patients on stable
dose and regimen of a single oral headache prophylaxis
medication for at least 4 weeks prior to Visit 2, the dose
may be changed at or after Visit 4 (Week 24). Those
patients who are not taking oral headache prophylaxis at
study entry must have discontinued their oral prophy-
laxis more than 4 weeks prior to Visit 1 to be eligible for
inclusion in the study. For patients not on oral headache
prophylaxis at Visit 2, a single oral prophylaxis medica-
tion such as a beta-blocker, calcium channel blocker,
ACE-inhibitor, aldosterone receptor blocker, antiepilep-
tic or tricyclic antidepressant may be added to the pa-
tient’s regimen as a component of the headache
prevention at or after Visit 4 (Week 24). If a patient is
receiving a medication listed as a headache prophylactic
that is specifically prescribed for a non‐headache condi-
tion, he or she is eligible to enter the study. They are
also eligible if receiving another agent on the headache
prophylactic list that has been prescribed for headache
as long as the prophylactic medication regimen is stable
for at least 4 weeks prior to Visit 1.
Patients may take abortive headache medications and
may add, change, or decrease these medications as
needed if recorded in the patient diary via IVRS. Medi-
cations that are both acute and prophylactic treatments
will be classified on the basis of the indication for use: if
they are specifically prescribed for daily use for headacheTable 2 Criteria for use of oral headache prophylaxis* in
COMPEL
Use of OHP Subjects Taking Single OHP
Prior to Visit 2 (Day 1)
Subjects Not Taking




Must be on stable dose and
regimen of single OHP for




— OHP may be added
after Visit 4 (Week 24)
Change of OHP
Dose
Dose may be changed at or




May occur at any time during study, but cannot be
replaced by same or other OHP
*Only a single concomitant OHP allowed during the study, and may include
tricyclic antidepressant, antiepileptic, beta-blocker, calcium channel blocker,
angiotensin enzyme (ACE) inhibitor, or angiotensin receptor blocker (ARB)
OHP = oral headache prophylaxis medicationprevention, they are considered to be prophylactic; if
they are used PRN by the patient (even for consecutive
days, weeks, or months), they are considered to be acute
medications. Patients with previous onabotulinumtoxinA
exposure or those with anticipated need for botulinum
toxin treatment for any reason during the study (other
than study treatment) will be excluded. To continue in
the COMPEL study after the 4-week baseline period,
participants must have documented ≥15 days of head-
ache per month with headache lasting 4 hours a day or
longer. Table 3 summarizes the inclusion and exclusion
criteria for COMPEL.Study treatment and efficacy measures
Patients who meet study criteria will receive 9 onabotuli-
numtoxinA treatments, administered during Visit 2 (Day
1) through Visit 10 (Week 96). Each treatment will con-
sist of a dose of 155 U of onabotulinumtoxinA adminis-
tered as 31 fixed-site, fixed-dose intramuscular (IM)
injections across 7 specific head and neck muscle areas
(Table 4).
The International Headache Society Clinical Trials
Guidelines Subcommittee for controlled trials of prophy-
lactic treatment of CM in adults [14] recommends that
the primary efficacy measure be based on the number of
headache days, reported by patient diaries. The primary
outcome in COMPEL is the mean change from baseline
in the frequency of headache days for the 28-day period
ending at Week 108 (following 9 treatments). Secondary
efficacy measures will include both mean change from
baseline in the frequency of headache days for the 28-
day period ending at Week 60 (following 5 treatments)
and mean change from baseline in HIT-6 total score
over 4 weeks at Week 108 (following 9 treatments) and
at Week 60 (following 5 treatments). The remaining
measures described are exploratory efficacy measures.
Efficacy measures based on daily diary entries and/or
baseline measures will include headache frequency, head-
ache duration (ie, whether headache lasts more than
4 hours), headache severity, and abortive headache medi-
cations used. Other measures, based on questionnaires
completed at Visit 1 (Screening) through Visit 11 (Week
108), will be as follows: HIT-6, MSQ v2.1, Migraine
Disability Assessment Questionnaire (MIDAS), Patient
Global Assessment of Treatment (PGAT), GAD-7, PHQ-
9, PSQI, FSS, 36-Item Short Form Survey Instrument (SF-
36), and healthcare resource utilization (ie, headache-
related visits to a healthcare professional, headache-related
visits to emergency room or urgent care, headache-related
admissions/overnights to a hospital, and headache-related
diagnostics in past 6 months) [15–21]. Table 5 includes a
short description of each measure that will be collected
and assessed in COMPEL in addition to headache days.
Table 3 Summary of main inclusion and exclusion criteria for
COMPEL
Inclusion Criteria
Male or female, ≥18 years of age on the day informed consent is
signed.
Diagnosis of chronic migraine (≥15 days per month with headache
lasting 4 hours a day or longer) with or without medication overuse.
History of chronic migraine (≥3 months).
Patients not taking oral headache prophylaxis medication must have
discontinued their oral prophylaxis ≥4 weeks prior to Visit 1.
Patients who are taking oral headache prophylaxis medication must be
on a stable dose and regimen of a single oral prophylaxis treatment
(prescribed for the use of headache prophylaxis) for at least 4 weeks
prior to Visit 2.
If a patient is receiving a headache prophylaxis medication that is
specifically prescribed for a non‐headache condition, he or she is
eligible to enter the study even if they are receiving another agent on
the headache prophylactic list that has been prescribed for headache,
as long as the non‐headache medication regimen is stable for at least
4 weeks prior to Visit 1.
Stable medical condition, in the investigator’s opinion.
Ability to follow study instructions (including compliance with a diary)
and likely to complete all required visits.
Negative urine pregnancy test at screening and on Day 1 prior to
administration of onabotulinumtoxinA (for females of childbearing
potential, including premenstrual women).
Documentation of ≥15 days of headache per month with headache
lasting 4 hours a day or longer by IVRS patient diary. If fewer than 28
(but more than 20) days are completed in the IVRS patient diary at Day
1, a minimum of 53.6 % of recorded diary days must have a headache
lasting 4 hours a day or longer.
Exclusion Criteria
Clinically significant medical condition other than the condition under
evaluation (including alcohol/illicit substance abuse, significant pain
condition [fibromyalgia, diabetic peripheral neuropathy, etc.]).
Any medical condition that may put the patient at increased risk with
exposure to botulinum toxin therapy of any serotype for consistency and
safety, including diagnosed myasthenia gravis, Eaton-Lambert syndrome,
amyotrophic lateral sclerosis, or any other significant disease that might
interfere with neuromuscular function.
Headache diagnosis of chronic tension-type headache (ICHD-III 2.3), cluster
headache (ICHD-III 3.1), hypnic headache (ICHD-III 4.9), or hemicrania
continua (ICHD-III 3.4).
Headache attributed to another disorder (ie, cervical dystonia,
craniotomy, head/neck trauma).
Severe major depressive disorder defined as BDI-II score >24.
Endorsement of a non-zero response on Item 9 (“Thoughts that you would
be better off dead, or hurting yourself in some way”) of the PHQ-9 (ie, Item
9 score≠ 0).
Females who are pregnant, nursing, or are planning a pregnancy during
the study.
Females of childbearing potential (including premenstrual women) who
are not using a reliable means of contraception.
Previous treatment with botulinum toxin of any serotype for any reason,
or immunization to any botulinum toxin serotype.
Anticipated need for botulinum toxin treatment for any reason during
the study (other than study treatment).
Known allergy or sensitivity to the study medication or its components.
Table 3 Summary of main inclusion and exclusion criteria for
COMPEL (Continued)
Previous participation in any botulinum toxin clinical trial.
Concurrent enrollment in an investigational drug or device study or
participation in such a study in the 4 weeks immediately prior to Visit 1.
Patient has a condition or is in a situation that, in the investigator's
opinion, may put the patient at significant risk, may confound the study
results, or may interfere significantly with the patient's participation in
the study.
Treatment of study target muscles using acupuncture, TENS, cranial
traction, dental splints for headache, nociceptive trigeminal inhibition,
occipital nerve block treatments, or injection of anesthetics/steroids
within 3 months prior to screening.
BDI-II = Beck Depression Inventory-II; COMPEL = Chronic migraine
OnabotulinuMtoxinA Prolonged Efficacy open Label study; ICHD-III = Inter-
national Classification of Headache Disorders, 3rd edition; IVRS = interactive voice
response system; PHQ-9 = Patient Health Questionnaire; TENS = transcutaneous
electrical nerve stimulation
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A key secondary objective of COMPEL is to evaluate the
long-term safety and tolerability (9 treatment cycles) of
onabotulinumtoxinA for CM in adult patients. Safety
and tolerability will be assessed by the frequency and na-
ture of adverse events (AEs) and physical examinations
including vital signs. Spontaneous AEs will be analyzed
starting on Day 1 (Visit 2), after injection; analysis will
continue through the end of the study period in all
patients who receive at least 1 injection of onabotuli-
numtoxinA. Any patient who exhibits change from base-
line in the response to Item 9 of the PHQ-9 (“Thoughts
that you would be better off dead, or hurting yourself in
some way”) any time during the study will consult with
the principal investigator about the suicidal ideation and
be withdrawn from the study. Patients who are with-













Procerus — — 5 (1 site)
Corrugator 5 (1 site) 5 (1 site) 10 (2 sites)
Frontalis 10 (2 sites) 10 (2 sites) 20 (4 sites)
Temporalis 20 (4 sites) 20 (4 sites) 40 (8 sites)





10 (2 sites) 10 (2 sites) 20 (4 sites)
Trapezius 15 (3 sites) 15 (3 sites) 30 (6 sites)
Total Dose — — 155 U (31 sites)
Source: [32]
a1 injection site = 0.1 milliliter (mL) = 5 U of onabotulinumtoxinA
Table 5 Secondary and additional efficacy measures to be collected in COMPEL
Measure Description
Headache Impact Test (HIT)-6 [33] • Measures impact of headache and treatment on individual's functional health and well-being.
• 6 domains: pain; role functioning (ability to carry out usual activities); social functioning; energy or
fatigue; cognition; and emotional distress.
Patient Global Assessment of Treatment
questionnaire (PGAT)




• Measures health-related quality-of-life impairments attributed to migraine.
• Divided into 3 domains: role function - restrictive (how migraines limit one’s daily social- and work-related
activities), role function - preventive (how migraines prevent these activities), and emotional function
(assesses the emotions associated with migraines).
Migraine Disability Assessment (MIDAS)
questionnaire [34]
• Assesses number of days that migraine prevented/limited activities in past 3 months, including paid
work, education, household work, and non-work activities (family, social, and leisure).
Generalized Anxiety Disorder Assessment
(GAD-7) [15]
• Measures frequency with which patients have been bothered by 7 symptoms of anxiety over the
previous 2 weeks.
Patient Health Questionnaire 9-item depres-
sion scale (PHQ-9) [35]
• Measures frequency with which patients have been bothered by 9 symptoms of depressive disorders
over the previous 2 weeks.
Pittsburgh Sleep Quality Index (PSQI) [18] • Measures the quality and patterns of sleep in 7 areas: subjective sleep quality; sleep latency; sleep
duration; habitual sleep efficiency; sleep disturbances; use of sleeping medication; and daytime
dysfunction over the previous month.
Fatigue Severity Scale (FSS) [19] • 9-item measure assessing the severity of fatigue and its impact on daily living.
Short Form Health Survey with 36 questions
(SF-36) [20]
• Generic, multipurpose 8-scale profile of functional health and well-being scores as well as psychometrically
based physical and mental health measures and preference-based health utility index.
Healthcare Resource Utilization (HRU) • HRU questionnaire data collected include medication use, healthcare visits, hospitalizations, and
emergency room visits.
Assessment of Chronic Migraine Impacts
(ACM-I)
• 24 questions about effect of migraines on one’s life, including daily activities, feelings, energy levels,
household, leisure activities, social activities, and work, over the previous 7 days.
Assessment of Chronic Migraine Symptoms
(ACM-S)
• 12 questions about migraine symptoms over the previous 24 hours, as a series of dichotomous yes/
no questions and others that are rated on a numeric rating scale of 0 to 10.
COMPEL = Chronic migraine OnabotulinuMtoxinA Prolonged Efficacy open Label study
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medical care and follow-up.
If a patient becomes pregnant at any time during the
study, she will be withdrawn. Specifically, if a female of
childbearing potential becomes pregnant during the
study, the patient will not receive any further injections
and will be followed for 12 weeks after the last study
treatment and at least 4 weeks since the pregnancy was
reported, before being exited from the study. The inves-
tigator will (1) notify the patient’s physician that the
patient was being treated with an investigational drug
onabotulinumtoxinA, and (2) follow the progress of the
pregnancy until delivery and document the outcome of
the pregnancy. Patients who are withdrawn from the
study will not receive further protocol-related injections
and will be referred to appropriate medical care and
follow-up.Statistical considerations: sample size and populations
Up to 40 investigative sites in the US, Australia, and South
Korea will enroll a sample size (N = 500 patients) that will
provide 80 % power to detect subgroup differences of 2.5
or more headache days as the primary endpoint with a95 % significance level. The safety population (SP) will in-
clude all patients who receive at least 1 onabotulinumtox-
inA treatment injection.
Ethical considerations
This study will be conducted in accordance with Institu-
tional Review Board (IRB) regulations (US 21 Code of
Federal Regulations [CFR] Part 56.103) or applicable
Independent Ethics Committee (IEC) regulations. This
protocol is to be conducted in accordance with the
applicable Good Clinical Practice (GCP) regulations and
guidelines. Written and informed consent will be ob-
tained from each patient or patient’s legally authorized
representative prior to enrollment into the study. The
Central IRB for the COMPEL Study was reviewed and
approved by the Quorum Review IRB in Seattle, WA.
Discussion
As evidenced by several population-based studies, CM
is a debilitating disease with extensive individual and
socioeconomic burden [3–5], yet only 33 % of CM
patients report taking prophylactic medications [3].
Aside from onabotulinumtoxinA, there are no currently
Table 6 Clinical trials of prophylaxis pharmacotherapy in chronic migraine
Treatment Evidence for Use in Chronic Migraine Number of Patients and Length of Trials
Anticonvulsants:
Valproate [25, 36] Small, double-blind, placebo-controlled trials in chronic migraine N = 70; 12 weeks (Yurekli et al. 2008)
N = 49; 12 weeks (Bartolini et al. 2005)
Topiramate [27, 28, 37] Double-blind, placebo-controlled trials in chronic migraine N = 28; 9 weeks (Silvestrini et al. 2003)
N = 59; 16 weeks (Diener et al. 2007)
N = 306; 16 weeks (Silberstein et al. 2007)
Gabapentin [26] One double-blind, placebo-controlled trial in chronic daily
headache
N = 133; 9 weeks (Spira et al. 2003)
Antidepressants:
Amitriptyline [38] Small, open-label trial in transformed migraine N = 27; 9 weeks (Krymchantowski et al.
2002)
Fluoxetine [24] Small, double-blind, placebo-controlled trial in chronic daily
headache
N = 64; 12 weeks (Saper et al. 1994)
Tizanidine [23] Small, double-blind, placebo-controlled trial in chronic daily
headache
N = 134; 12 weeks (Saper et al. 2002)
Botulinum Toxin:
OnabotulinumtoxinA [29, 30] Large, double-blind, placebo-controlled trials in CM N = 679; 56 weeks (Aurora et al. 2010)
N = 705; 56 weeks (Diener et al. 2010)
Comparison of 2 Therapies:
OnabotulinumtoxinA vs Topiramate
[39, 40]
Small, double-blind, pilot trials in CM N = 60; 12 weeks (Mathew et al. 2009)
N = 59; 26 weeks (Cady et al. 2011)
CM = chronic migraine
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There are four botulinum toxin products approved in the
US for other indications; three are serotype A (onabotuli-
numtoxinA [BOTOX®, Allergan, Inc., Irvine, CA, USA],
abobotulinumtoxinA [Dysport®, Ipsen, Paris, France], and
incobotulinumtoxinA [Xeomin®, Merz PharmaceuticalsFig. 2 PREEMPT 56-week data showed continued improvement in headach
of PREEMPT 1 and 2: the double-blind phase included 688 subjects in the o
days at baseline: 19.9 onabotulinumtoxinA group vs 19.8 placebo group, p
Prophylaxis TherapyGmbH, Frankfurt, Germany]); and one is serotype B
(rimabotulinumtoxinB [Myobloc®/Neurobloc®, Solstice
Neuroscience, San Francisco, CA, USA]). Each differs in
molecular structure, formulation, and clinical profile.
There is no international potency reference standard for
botulinum toxins, and each formulation of botulinume days with onabotulinumtoxinA. Source: [31]. This is a pooled analysis
nabotulinumtoxinA group and 696 in the placebo group. Headache
= 0.498. PREEMPT = Phase 3 REsearch Evaluating Migraine
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cific to each product and not interchangeable with those
of any other botulinum toxins [22].
Several pharmacological agents have been evaluated in
small (≤200 patients) double-blind, placebo-controlled
studies for prophylaxis of CM [23–27]. In addition to
studying a small population, these were generally short-
term trials, with the longest study lasting approximately
7 months [28]. Table 6 presents an overview of the clin-
ical trials that have been conducted in a CM population.
The PREEMPT clinical program utilized a set of
clearly defined diagnostic criteria and outcome mea-
sures to assess the safety and efficacy of onabotulinum-
toxinA in the prophylaxis of headache in CM patients.
PREEMPT consists of the 2 longest CM trials to date (a
24-week, double-blind period followed by a 32-week,
open-label phase) [29, 30]. However, this study did not
evaluate the effects of onabotulinumtoxinA treatment past
56 weeks [31]. Consequently, the 108-week COMPEL
study aims to assess the efficacy, safety, and tolerability of
onabotulinumtoxinA as long-term headache prophylaxis
in adult patients with CM.
To our knowledge, COMPEL will be the longest CM
trial ever conducted and is expected to add significant
knowledge to the literature about long-term use of prophy-
lactic therapy in this patient population. At 15 months, pa-
tients who received onabotulinumtoxinA in the PREEMPT
study continued to show divergence from those who re-
ceived placebo during the double-blind phase (Fig. 2);
COMPEL will evaluate whether there is continued im-
provement with onabotulinumtoxinA treatment through
108 weeks, and may or may not demonstrate when a
plateau is established. Further, detailed information about
the effect of onabotulinumtoxinA on measures other than
the primary headache variables will be determined in
COMPEL.
Although open-label studies augment knowledge learned
from phase 3 randomized controlled trials, they have inher-
ent limitations. One limitation of our study involves its
nonrandomized, open-label design. In addition, an open-
label design with long-term follow up can be subject to
multiple confounders such as unintentional bias, low
persistency rates, and concomitant medication changes.
Although steps have been taken to control for concomitant
medications and headache medication use, stabilization of
dose may not always be possible in patients once enrolled.
Finally, COMPEL will capture comorbidities in this patient
population; however, not all comorbidities will be captured
and patients with severe depressive symptoms and suicidal
ideation will be excluded.
In conclusion, COMPEL may provide important clinical
guidance for physicians by studying treatment outcomes
with onabotulinumtoxinA in the presence of oral prophy-
lactics and measuring the effect of onabotulinumtoxinAon a number of exploratory measures, including the as-
sessment of chronic disease comorbidities such as sleep,
fatigue, and anxiety. Healthcare resource utilization will be
measured, and an extensive number of patient-reported
outcomes will be assessed. Through multiple measures,
COMPEL may contribute data to improve our under-
standing of the long-term effects of onabotulinumtoxinA
treatment on CM patients.
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